Cell Disruption Homogenization Patents: Leaders & White Space 2026
- 15.4% concentration at the top. The five leading assignees hold 117 of 761 records in scope — a real lead, not a monopoly, with a long tail of single- and few-filing entrants behind them.
- Filing has cooled from its 2019 peak of 65. The 2021→2024 span shows a 55% decline (20 to 9 records), though 2025-2026 counts are still filling in under an 18-month publication lag.
- C12P and C12M sit well behind C12N. Fermentation/enzymatic synthesis (30.7%) and bioreactor apparatus (23.0%) trail the dominant microorganism/genetic-engineering class (93.4%), marking where claim density thins out.
Filing growth compares 2021 (20 records) with 2024 (9) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 761 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent activity at the intersection of cell disruption and lysis and the mechanical parameters that govern it: high pressure, orifice geometry, pressure drop, pass number, cell breakage and product release. The search spans 761 published records filed against IPC classes covering microorganism handling, comminution equipment and chemical/physical processing apparatus. It captures methods, devices and process claims used across biomanufacturing, industrial biotechnology and diagnostic sample-prep workflows.
Coverage runs from 2015 through the 2026-07-31 cut-off. Because publication typically lags filing by roughly 18 months, the most recent one to two years understate real filing activity and should not be read as a decline on their own.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 761 records: how filing activity has moved year over year, and how it distributes across the eight IPC subclasses that appear most often in scope.
Filing trend, 2017-2026
Annual filings rose from 10 in 2017 to a peak of 65 in 2019, then eased. The tracked 2021-to-2024 window fell 55%, from 20 to 9 records; treat 2025 and 2026 as incomplete rather than confirmation of a continued drop.
Technology composition by IPC subclass
C12N (microorganisms and genetic engineering) appears in 93.4% of the 761 records, effectively a gating classification for this search. C12P (30.7%) and C12M (23.0%) follow at a real distance, with C07K, C12Q, G01N, A61K and A23L each present in roughly one in eight to one in ten records — evidence of secondary but non-trivial claim activity in protein recovery, analytics and food-grade extraction.
Shares are the percentage of the 761 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cell Disruption Mechanical Homogenization with Eureka
This page is one run against one query. Ask Eureka your own question about cell disruption mechanical homogenization and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a representative filing
US20230203428A1 — Methods of improving intracellular biomolecule extraction yield and methods of cell lysis
Filed by Arizona State University (Arizona Board of Regents), this application describes storing microbial cells under ultra-low temperature conditions for at least 10 minutes prior to lysis, as a step intended to improve downstream extraction yield of intracellular biomolecules.Published 2023-06-29.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20050170479A1 | Method for producing lipids by liberation from biomass | 306 |
| 2 | US7238522B2 | Devices and methods for biomaterial production | 248 |
| 3 | US5374522A | Method for releasing RNA and DNA from cells | 169 |
| 4 | US6274726B1 | Pressure-enhanced extraction and purification | 149 |
| 5 | US5789542A | Amphipathic peptides | 129 |
| 6 | WO2003008636A2 | Universal method and composition for the rapid lysis of cells for the release of nucleic acids and their dete… | 112 |
| 7 | US20100291536A1 | Sample processing cassette, system, and method | 104 |
| 8 | US4683293A | Purification of pichia produced lipophilic proteins | 103 |
| 9 | US6120985A | Pressure-enhanced extraction and purification | 102 |
| 10 | US6111096A | Nucleic acid isolation and purification | 101 |
Citation counts accumulate over time and favour older filings; read them as a signal of influence within this corpus, not as a marker of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns worth acting on before drafting new claims or scoping freedom-to-operate.
Leadership is real but not exclusionary
The top five assignees hold 117 records (15.4% of all 761 in scope) and the top ten hold 197 (25.9%). That leaves roughly three-quarters of the field to the remaining 90 ranked assignees plus unranked filers — enough room for a differentiated entrant, but not a wide-open field.
Activity has cooled from its 2019 peak
Filing peaked at 65 records in 2019 and has since declined; the tracked three-year window from 2021 to 2024 shows a 55% drop. Because 2025-2026 filings are still being published, this should be read as a real slowdown through 2024, not as an ongoing collapse.
Apparatus claims trail method claims by a wide margin
C12N (microorganism/genetic engineering methods) touches 93.4% of records, while C12M (bioreactor and enzyme apparatus) appears in only 23.0%. The gap suggests hardware-specific claims around orifice geometry, pass number and pressure-drop control are comparatively less crowded than method claims covering the biological material itself.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell disruption mechanical homogenization, with the prior art for and against each one.
Who is filing, and where the field is still open
The ranked leaders span industrial biotech, diagnostics and specialty ingredients; recent-year filing counts show most established names have gone quiet, which is as informative as the historical totals.
A single leader sits ahead of a tightly packed group
The top-ranked assignee holds 26 records against a fifth-place figure of 20 and a tenth-place figure of 15 — a gradual taper rather than a sharp cliff, consistent with a field where scale advantages exist but are not decisive.
Most historical leaders show no recent-year filings
Several assignees with substantial historical totals recorded zero filings in the latest tracked year, and at least one shows a -100% year-on-year change. This is consistent with the broader publication lag but also suggests some incumbents have shifted filing elsewhere or paused activity.
Collaboration is limited and concentrated
Only nine co-assignee pairs appear across the dataset, and the strongest pair co-files at a modest scale. Most activity in this field is filed by a single assignee rather than through joint ventures or research partnerships.
| Assignee | Recent year | YoY |
|---|---|---|
| Corbion Biotech Inc | 2 | — |
| Genentech Inc | 0 | — |
| Ohly GmbH | 0 | -100% |
| Jupeng Bio Inc | 0 | — |
| Vlaamse Instelling voor Technologisch Onderzoek NV (VITO) | 0 | — |
| International N&H Denmark ApS | 0 | — |
| Cepheid Inc | 0 | — |
| Pressure BioSciences Inc | 0 | — |
Where to take this next
The numbers point to a field with a defined method-claim core and comparatively open apparatus and analytics branches.
Scope freedom-to-operate around the top 10
With 25.9% of records held by the top ten assignees, a targeted FTO review of their claim families is a faster first step than reviewing the full ranked set.
Explore assignee claims in EurekaTrack the apparatus-side gap
The C12N/C12M gap (93.4% vs 23.0%) suggests hardware claims around orifice geometry and pass-number control warrant closer drafting attention.
Run a white-space search in EurekaRevisit the 2025-2026 window later
Because publication lags filing by roughly 18 months, re-check filing counts for 2025 and 2026 once they stabilise before drawing conclusions about a continued slowdown.
Set up monitoring in EurekaCommon questions on this landscape
This dataset contains 761 published patent records filed between 2015 and the 2026-07-31 cut-off, matched against terms like high pressure, orifice geometry, pass number and cell breakage combined with cell disruption and lysis language. The records span IPC classes for microorganism handling, comminution equipment and chemical/physical process apparatus. Because families rather than raw filings are counted, this figure is a fair basis for comparing filing volume across assignees and years.
The ranking covers 100 assignees, with the leader holding 26 of the 761 records in scope and the top five combined holding 117 records (15.4% of the total). That leaves the majority of filings spread across a long tail of smaller and single-filing entrants, so no one company controls the field outright. Recent-year filing counts also show several historically large filers with zero filings in the latest tracked year, which is worth checking before assuming current market position matches historical totals.
Filing peaked at 65 records in 2019 and has since cooled; the tracked 2021-to-2024 window shows a 55% decline, from 20 records down to 9. However, patent publication typically lags actual filing by around 18 months, so the 2025 and 2026 counts in this dataset are still incomplete and should not be read as confirming an ongoing drop. The safest read is that activity slowed through 2024, with the most recent picture still forming.
US20230203428A1, filed by Arizona State University's Board of Regents, describes a method of improving intracellular biomolecule extraction yield by storing microbial cells under ultra-low temperature conditions for at least 10 minutes before lysis. It is a process-timing and pre-treatment claim rather than a device or apparatus claim, so it primarily affects workflows that lyse cryo-stored biomass. Anyone using a cold-storage pre-treatment step ahead of mechanical or chemical lysis should review this filing's claim scope directly rather than relying on the abstract alone.
The clearest gap sits between the method-heavy C12N classification, present in 93.4% of the 761 records, and apparatus-focused classes like C12M, present in only 23.0%. This suggests that hardware-specific claims around orifice geometry, multi-pass pressure control and bioreactor-integrated lysis equipment are less densely claimed than the underlying biological methods. Food-grade extraction hardware and inline yield-sensing during lysis also show comparatively thin coverage relative to the core method claims.
Research Cell Disruption Mechanical Homogenization in depth with Eureka
Go past this page: query the whole cell disruption mechanical homogenization corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.